-
Subject Areas on Research
-
(18)F-FDG PET/CT and Melanoma: Staging, Immune Modulation and Mutation-Targeted Therapy Assessment, and Prognosis.
-
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC).
-
A Blueprint to Advance Colorectal Cancer Immunotherapies.
-
A Gene Mutation Signature Predicting Immunotherapy Benefits in Patients With NSCLC.
-
A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples.
-
A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience.
-
A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma.
-
A Southeastern Cancer Study Group phase I/II trial with vaccinia melanoma oncolysates.
-
A comparison of alemtuzumab with basiliximab induction in simultaneous pancreas-kidney transplantation.
-
A genomic approach to improve prognosis and predict therapeutic response in chronic lymphocytic leukemia.
-
A global approach to tumor immunology.
-
A multidisciplinary approach to toxicity management of modern immune checkpoint inhibitors in cancer therapy.
-
A multiphase immunotherapy regimen for human melanoma: clinical and laboratory results.
-
A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701.
-
A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903.
-
A phase II study of tamoxifen combined with cisplatin-interleukin 2 and alpha-interferon in metastatic melanoma.
-
A preliminary study utilizing viable HLA mismatched cultured glioma cells as adjuvant therapy for patients with malignant gliomas.
-
A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.
-
A promising cancer vaccine.
-
A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer.
-
A reevaluation of CD22 expression in human lung cancer.
-
A review of cancer immunotherapy toxicity.
-
A review of glioblastoma immunotherapy.
-
A self-assembling peptide acting as an immune adjuvant.
-
A single genetic locus determines the efficacy of serum therapy against murine adenocarcinoma 755a.
-
A study of dendritic and endothelial cell interactions in colon cancer in a cell line and small mammal model.
-
A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy.
-
A urologic oncology roundtable discussion: issues to consider in choosing treatment for metastatic castration-resistant prostate cancer.
-
ADAM metallopeptidase domain 17 (ADAM17) is naturally processed through major histocompatibility complex (MHC) class I molecules and is a potential immunotherapeutic target in breast, ovarian and prostate cancers.
-
AIDS and HIV infection.
-
AIDS-related cytomegalovirus retinitis: lessons from the laboratory.
-
APOBEC Mutagenesis Inhibits Breast Cancer Growth through Induction of T cell-Mediated Antitumor Immune Responses.
-
ATM inhibition enhances cancer immunotherapy by promoting mtDNA leakage and cGAS/STING activation.
-
Abnormalitieis of monocyte chemotaxis in patients with melanoma: effects of immunotherapy and tumor removal.
-
Activation of matrix metalloproteinases following anti-Aβ immunotherapy; implications for microhemorrhage occurrence.
-
Active immunization with tumor cells transduced by a novel AAV plasmid-based gene delivery system.
-
Active immunotherapy of pancreatic cancer with tumor cells genetically engineered to secrete multiple cytokines.
-
Active immunotherapy with transiently transfected cytokine-secreting tumor cells inhibits breast cancer metastases in tumor-bearing animals.
-
Active specific immunotherapy of Dukes B2 and C colorectal carcinoma: comparison of two doses of the vaccine.
-
Adeno-associated virus vectors: potential applications for cancer gene therapy.
-
Adenosine deaminase and purine nucleoside phosphorylase deficiencies: evaluation of therapeutic interventions in eight patients.
-
Adjuvant Systemic Therapies for Patients with Renal Cell Carcinoma: Choosing Treatment Based on Patient-level Characteristics.
-
Adjuvanted Immunotherapy Approaches for Peanut Allergy.
-
Adoptive transfer and specific active immunization of patients with malignant melanoma.
-
Advanced Melanoma: Resistance Mechanisms to Current Therapies.
-
Advances and challenges: dendritic cell vaccination strategies for glioblastoma.
-
Advances in immunotherapy for pancreatic cancer: 2013.
-
Advances in myasthenia gravis.
-
Advances in the diagnosis and treatment of primary immunodeficiency diseases.
-
Affinity-matured recombinant immunotoxin targeting gangliosides 3'-isoLM1 and 3',6'-isoLD1 on malignant gliomas.
-
Age cutoff in lymphoma diagnosis.
-
Alliance A082002 -a randomized phase II/III trial of modern immunotherapy-based systemic therapy with or without SBRT for PD-L1-negative, advanced non-small cell lung cancer.
-
Alpha-fetoprotein-specific genetic immunotherapy for hepatocellular carcinoma.
-
Altered expression of TIM-3, LAG-3, IDO, PD-L1, and CTLA-4 during nimotuzumab therapy correlates with responses and prognosis of oral squamous cell carcinoma patients.
-
An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma.
-
An unbiased in vivo functional genomics screening approach in mice identifies novel tumor cell-based regulators of immune rejection.
-
An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma.
-
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.
-
Anti-HIV-1 ADCC: clinical and therapeutic implications.
-
Anti-PD-L1 antibody direct activation of macrophages contributes to a radiation-induced abscopal response in glioblastoma.
-
Anti-amyloid therapy protects against retinal pigmented epithelium damage and vision loss in a model of age-related macular degeneration.
-
Anti-amyloid-beta immunotherapy in Alzheimer's disease: relevance of transgenic mouse studies to clinical trials.
-
Anti-angiogenic therapy for malignant solitary fibrous tumour: validation through collaboration.
-
Anti-tumor immunotherapy despite immunity to adenovirus using a novel adenoviral vector Ad5 [E1-, E2b-]-CEA.
-
Antibiotics and Immunotherapy: Too Much of Anything is Bad!
-
Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors.
-
Antibody-based immunotherapy for malignant glioma.
-
Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy.
-
Antigen-loaded monocyte administration induces potent therapeutic antitumor T cell responses.
-
Antigen-presenting cells pulsed with unfractionated tumor-derived peptides are potent tumor vaccines.
-
Aptamers in immunotherapy.
-
Aristolochic acids and their derivatives are widely implicated in liver cancers in Taiwan and throughout Asia.
-
Aspects of immunobiology and immunotherapy and uses of monoclonal antibodies and biologic immune modifiers in human gliomas.
-
Assessing surrogacy using restricted mean survival time ratio for overall survival in non-small cell lung cancer immunotherapy studies.
-
Augmentation of tumor-specific immunity by upregulation of apoptotic melanoma cell calreticulin expression.
-
Autoimmune disorders of neuromuscular transmission.
-
Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity.
-
Autologous Dendritic Cell-Cytokine Induced Killer Cell Immunotherapy Combined with S-1 Plus Cisplatin in Patients with Advanced Gastric Cancer: A Prospective Study.
-
Autologous lymph node cell-derived tumor-specific cytotoxic T-cells for use in adoptive immunotherapy of human melanoma.
-
B cells in chronic graft-versus-host disease.
-
B cells in the pathophysiology of myasthenia gravis.
-
B-lymphocyte contributions to human autoimmune disease.
-
BTN3A1 governs antitumor responses by coordinating αβ and γδ T cells.
-
Bimodal liquid biopsy for cancer immunotherapy based on peptide engineering and nanoscale analysis.
-
Biomarkers and correlative endpoints for immunotherapy trials.
-
Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond.
-
Biomaterial interactions with the immune system.
-
Bladder cancer.
-
Blood microbiota diversity determines response of advanced colorectal cancer to chemotherapy combined with adoptive T cell immunotherapy.
-
Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors.
-
Brain Tumor Microenvironment and Host State: Implications for Immunotherapy.
-
Brain immunology and immunotherapy in brain tumours.
-
CD122-Selective IL2 Complexes Reduce Immunosuppression, Promote Treg Fragility, and Sensitize Tumor Response to PD-L1 Blockade.
-
CD20: a regulator of cell-cycle progression of B lymphocytes.
-
CD22: a multifunctional receptor that regulates B lymphocyte survival and signal transduction.
-
CD38-NAD+Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response.
-
CD40 ligand is essential for generation of specific cytotoxic T cell responses in RNA-pulsed dendritic cell immunotherapy.
-
CD98-induced CD147 signaling stabilizes the Foxp3 protein to maintain tissue homeostasis.
-
CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1.
-
COVID-19 vaccines for patients with cancer: benefits likely outweigh risks.
-
CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer.
-
Can I Get a Multidisciplinary Consult, Please? Systemic Immunotherapy and the Timing of Cytoreductive Nephrectomy.
-
Can you tBID on it?
-
Cancer Moonshot Immuno-Oncology Translational Network (IOTN): accelerating the clinical translation of basic discoveries for improving immunotherapy and immunoprevention of cancer.
-
Cancer immunotherapy innovator James Allison receives the 2015 Lasker~DeBakey Clinical Medical Research Award.
-
Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen-specific CTLs.
-
Cancer vaccines in colon and rectal cancer over the last decade: lessons learned and future directions.
-
Cell binding and tumor inhibiting functions of a new antihuman melanoma murine monoclonal antibody.
-
Cellular and biological therapies of gastrointestinal tumors: overview of clinical trials.
-
Certolizumab pegol.
-
Challenges in the pursuit of immune tolerance.
-
Checking the Hippo in Sarcomatoid Renal Cell Carcinoma with Immunotherapy.
-
Checkpoint inhibitor immunotherapy for glioblastoma: current progress, challenges and future outlook.
-
Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma.
-
Clinical Trials in Melanoma: Margins, Lymph Nodes, Targeted and Immunotherapy.
-
Clinical Trials with Biologic Primary Endpoints in Immuno-oncology: Concepts and Usage.
-
Clinical applications of a peptide-based vaccine for glioblastoma.
-
Clinical applications of dendritic cell vaccines.
-
Clinical immunotherapy for brain tumors.
-
Combination immunotherapy and radiotherapy causes an abscopal treatment response in a mouse model of castration resistant prostate cancer.
-
Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity.
-
Combination strategies to maximize the benefits of cancer immunotherapy.
-
Combination treatment of murine tumors by adenovirus-mediated local B7/IL12 immunotherapy and radiotherapy.
-
Combinations of Bevacizumab With Cancer Immunotherapy.
-
Combining cancer vaccines with chemotherapy.
-
Combining immunotherapy and radiotherapy for the STAR treatment.
-
Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology.
-
Commentary: Induction Immunotherapy: Intriguing Initiative for Investigation.
-
Commentary: Induction immunotherapy for esophageal cancer: A safe start.
-
Comparative analysis of antigen loading strategies of dendritic cells for tumor immunotherapy.
-
Comparison of intratumoral bolus injection and convection-enhanced delivery of radiolabeled antitenascin monoclonal antibodies.
-
Complement Factor H Antibodies from Lung Cancer Patients Induce Complement-Dependent Lysis of Tumor Cells, Suggesting a Novel Immunotherapeutic Strategy.
-
Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life.
-
Concerted potent humoral immune responses to autoantigens are associated with tumor destruction and favorable clinical outcomes without autoimmunity.
-
Concise Review: Modulating Cancer Immunity with Hematopoietic Stem and Progenitor Cells.
-
Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy.
-
Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors.
-
Construction and preclinical characterization of Fc-mGITRL for the immunotherapy of cancer.
-
Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma.
-
Continuous DC-CIK infusions restore CD8+ cellular immunity, physical activity and improve clinical efficacy in advanced cancer patients unresponsive to conventional treatments.
-
Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors.
-
Cotransfection of DC with TLR4 and MART-1 RNA induces MART-1-specific responses.
-
Countering tumor-induced immunosuppression during immunotherapy for pancreatic cancer.
-
Critical care perspective on immunotherapy in lung transplantation.
-
Curing HIV: Seeking to Target and Clear Persistent Infection.
-
Current immunotherapeutic strategies in colon cancer.
-
Current immunotherapeutic strategies in malignant melanoma.
-
Current management of melanoma.
-
Current status of dendritic cell immunotherapy of malignancies.
-
Cytokine and immuno-gene therapy for solid tumors.
-
Cytokine expression in vivo during murine herpetic stromal keratitis. Effect of protective antibody therapy.
-
Cytokine-Mediated Tissue Injury in Non-human Primate Models of Viral Infections.
-
DC-CIK as a widely applicable cancer immunotherapy.
-
DNA array-based gene profiling in tumor immunology.
-
DNA-based immunotherapy to treat atopic disease.
-
Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer.
-
Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee.
-
Delivery of Synthetic mRNA Encoding FOXP3 Antigen into Dendritic Cells for Inflammatory Breast Cancer Immunotherapy.
-
Dendritic Cell Immunotherapy for HIV-1 Infection Using Autologous HIV-1 RNA: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
-
Dendritic cell maturation in active immunotherapy strategies.
-
Dendritic cell-based immunization for cancer therapy.
-
Dendritic cell-based immunotherapy.
-
Dendritic cell-tumor cell fusion vaccines.
-
Dendritic cells activate antitumor immunity for malignant intracranial germ cell tumor: a case report.
-
Dendritic cells pulsed with pancreatic cancer total tumor RNA generate specific antipancreatic cancer T cells.
-
Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma.
-
Detection of amino-terminal extracellular domain of somatostatin receptor 2 by specific monoclonal antibodies and quantification of receptor density in medulloblastoma.
-
Developing treatment guidelines for myasthenia gravis.
-
Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy.
-
Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer.
-
Disorders of human leukocyte chemotaxis.
-
Dissecting the Functional Significance of DNA Polymerase Mutations in Cancer.
-
Distant cutaneous granulomas after bacille Calmette-Guérin immunotherapy for malignant melanoma: case for direct infection.
-
Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms.
-
Diverse inflammatory responses in transgenic mouse models of Alzheimer's disease and the effect of immunotherapy on these responses.
-
Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies.
-
Dose-intense chemoimmunotherapy plus radioimmunotherapy in high-risk diffuse large B-cell lymphoma and mantle cell lymphoma: a phase II study.
-
Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells.
-
Dysfunctional T cell metabolism in the tumor microenvironment.
-
EGF mutant receptor vIII as a molecular target in cancer therapy.
-
EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma.
-
EGFRvIII-targeted vaccination therapy of malignant glioma.
-
Effect of Anti-C5a Therapy in a Murine Model of Early/Intermediate Dry Age-Related Macular Degeneration.
-
Effect of Targeted Therapies on Prognostic Factors, Patterns of Care, and Survival in Patients With Renal Cell Carcinoma and Brain Metastases.
-
Effect of adriamycin and Corynebacterium parvum in tumor-bearing mice: modulation of response to sheep red blood cells.
-
Effective antibody therapy in herpes simplex virus ocular infection. Characterization of recipient immune response.
-
Effects of hyperthermia and irradiation on the growth of mouse melanoma tumors following immunotherapy.
-
Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma.
-
Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial.
-
Emerging clinical applications of RNA.
-
Emerging immunotherapies for autoimmune kidney disease.
-
Emerging immunotherapies for glioblastoma.
-
Emerging nanotechnology approaches for HIV/AIDS treatment and prevention.
-
Emerging therapeutics for ocular surface disease.
-
Emerging treatment options for patients with castration-resistant prostate cancer.
-
Endogenous Retrovirus Activation as a Key Mechanism of Anti-Tumor Immune Response in Radiotherapy.
-
Engaging Pattern Recognition Receptors in Solid Tumors to Generate Systemic Antitumor Immunity.
-
Engineering challenges for brain tumor immunotherapy
-
Enhanced dendritic cell antigen presentation in RNA-based immunotherapy.
-
Enhanced in vivo cytotoxicity of recombinant human tumor necrosis factor with etoposide in human renal cell carcinoma. Evaluation in a pre-clinical model.
-
Enhanced macrophage tumoricidal activity and tumor suppression or regression caused by heat-killed Candida albicans.
-
Enhancing the immunostimulatory function of dendritic cells by transfection with mRNA encoding OX40 ligand.
-
Envelope-specific antibodies and antibody-derived molecules for treating and curing HIV infection.
-
EpCAM: A new therapeutic target for an old cancer antigen.
-
Epidermal growth factor receptor and variant III targeted immunotherapy.
-
Eradication of melanoma pulmonary metastases by immunotherapy with tumor cells engineered to secrete interleukin-2 or gamma interferon.
-
Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer.
-
Evidence of neuroinflammation and immunotherapy responsiveness in individuals with down syndrome regression disorder.
-
Evidence-based medical oncology and interventional radiology paradigms for liver-dominant colorectal cancer metastases.
-
Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer.
-
Ex Vivo Tumor-on-a-Chip Platforms to Study Intercellular Interactions within the Tumor Microenvironment.
-
Exercise as Adjunct Therapy in Cancer.
-
Expanding anti-CD38 immunotherapy for lymphoid malignancies.
-
Expression of FMS-like tyrosine kinase 3 ligand by oncolytic herpes simplex virus type I prolongs survival in mice bearing established syngeneic intracranial malignant glioma.
-
Expression of MAGE and GAGE in high-grade brain tumors: a potential target for specific immunotherapy and diagnostic markers.
-
Expression of intercellular adhesion molecule (ICAM)-1 or ICAM-2 is critical in determining sensitivity of pancreatic cancer cells to cytolysis by human gammadelta-T cells: implications in the design of gammadelta-T-cell-based immunotherapies for pancreatic cancer.
-
Facts and Hopes for Immunotherapy in Renal Cell Carcinoma.
-
Fcgamma receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity.
-
Fine tuning of immunometabolism for the treatment of rheumatic diseases.
-
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer.
-
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia.
-
Follicle-Stimulating Hormone Receptor Is Expressed by Most Ovarian Cancer Subtypes and Is a Safe and Effective Immunotherapeutic Target.
-
Frequency and impact of grade three or four toxicities of novel agents on outcomes of older patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma (alliance A151611).
-
From the RNA world to the clinic.
-
Fulfilling the promise of immunotherapy.
-
Future therapies for food allergy.
-
GLP toxicology study of a fully-human T cell redirecting CD3:EGFRvIII binding immunotherapeutic bispecific antibody.
-
Galectin-1 drives lymphoma CD20 immunotherapy resistance: validation of a preclinical system to identify resistance mechanisms.
-
Gating Harmonization Guidelines for Intracellular Cytokine Staining Validated in Second International Multiconsortia Proficiency Panel Conducted by Cancer Immunotherapy Consortium (CIC/CRI).
-
Gene Expression Profile of Dendritic Cell-Tumor Cell Hybrids Determined by Microarrays and Its Implications for Cancer Immunotherapy.
-
Gene expression signatures of interleukin-2 in vivo and in vitro and their relation to anticancer therapy.
-
Gene therapy and pancreatic cancer.
-
Gene therapy for prostate cancer.
-
Gene- and cell-based approaches for neurodegenerative disease.
-
Generation of anti-idiotypic reagents in the EGFRvIII tumor-associated antigen system.
-
Generation of human IgG, IgA, and IgM anti-melanoma monoclonal antibodies utilizing lymphocytes of an actively immunized melanoma patient.
-
Genetically stable poliovirus vectors activate dendritic cells and prime antitumor CD8 T cell immunity.
-
Global role of the immune system in identifying cancer initiation and limiting disease progression.
-
Gold nanoparticles-mediated photothermal therapy and immunotherapy.
-
Gorlin syndrome and desmoplastic medulloblastoma: Report of 3 cases with unfavorable clinical course and novel mutations.
-
Graft versus leukemia effect in man: the relapse rate of acute leukemia is lower after allogeneic than after syngeneic marrow transplantation.
-
Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms.
-
Graft-versus-leukemia in man: relationship of acute and chronic graft-versus-host disease to relapse of acute leukemia following allogeneic bone marrow transplantation.
-
Growth effects of epidermal growth factor (EGF) and a monoclonal antibody against the EGF receptor on four glioma cell lines.
-
Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic.
-
HIV antibodies for treatment of HIV infection.
-
Hepatocellular Carcinoma-The Influence of Immunoanatomy and the Role of Immunotherapy.
-
High dose immunotherapy with stem cell rescue in severe systemic sclerosis: an idea that is moving forward.
-
High-dose interleukin-2 therapy related adverse events and implications on imaging.
-
Highly conserved gene expression profiles in humans with allergic rhinitis altered by immunotherapy.
-
Hoping for the best and preparing for the worst: a forgotten maxim in the immunotherapy era?
-
Host-Directed Therapies for Tuberculosis.
-
How can we create precision immunotherapy as standard in breast cancer?
-
Human T cells specifically activated against autologous malignant melanoma.
-
Human cytotoxic T cells specific for autologous melanoma cells: successful generation from lymph node cells in seven consecutive cases.
-
Human xenograft-nude mouse model of adoptive immunotherapy with human melanoma-specific cytotoxic T-cells.
-
Humoral and Innate Antiviral Immunity as Tools to Clear Persistent HIV Infection.
-
Hyperthermia-regulated immunogene therapy.
-
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.
-
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.
-
Identification of a Germline Pyrin Variant in a Metastatic Melanoma Patient With Multiple Spontaneous Regressions and Immune-related Adverse Events.
-
Identification of a tumor associated antigen that can induce tumor specific cytotoxicity.
-
Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer.
-
Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer.
-
Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy.
-
IgE, allergy, and risk of glioma: update from the San Francisco Bay Area Adult Glioma Study in the temozolomide era.
-
Immune Activation in Early-Stage Non-Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab.
-
Immune Checkpoint Blockade: The New Frontier in Cancer Treatment.
-
Immune Checkpoint Inhibitor-associated Uveitis: Review of Treatments and Outcomes.
-
Immune Checkpoint Inhibitors for Brain Metastases.
-
Immune Checkpoint Inhibitors for Treatment of Metastatic Melanoma of the Orbit and Ocular Adnexa.
-
Immune Checkpoint Inhibitors in Gliomas.
-
Immune Microenvironment Landscape in CNS Tumors and Role in Responses to Immunotherapy.
-
Immune expression in children with Wilms tumor: a pilot study.
-
Immune signatures of murine and human cancers reveal unique mechanisms of tumor escape and new targets for cancer immunotherapy.
-
Immuno-prophylaxis and -therapy of C-type oncorna viral diseases in mice and cats.
-
Immuno-synergy? Neoantigen vaccines and checkpoint blockade in glioblastoma.
-
Immunobiologic aspects of the brain and human gliomas. A review.
-
Immunobiology of human gliomas.
-
Immunobiology of primary intracranial tumors.
-
Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909.
-
Immunogenic cancer cell death selectively induced by near infrared photoimmunotherapy initiates host tumor immunity.
-
Immunogenicity of AGS-004 Dendritic Cell Therapy in Patients Treated During Acute HIV Infection.
-
Immunogenicity of dendritic-tumor fusion hybrids and their utility in cancer immunotherapy.
-
Immunoglobulin prophylaxis in patients with antibody deficiency syndromes and anti-IgA antibodies.
-
Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies.
-
Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study.
-
Immunomodulation for glioblastoma.
-
Immunonanoshells for targeted photothermal ablation in medulloblastoma and glioma: an in vitro evaluation using human cell lines.
-
Immunonanoshells for targeted photothermal ablation of tumor cells.
-
Immunoproteasome down-modulation enhances the ability of dendritic cells to stimulate antitumor immunity.
-
Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer.
-
Immunotherapeutic targeting of Wilms' tumor protein.
-
Immunotherapy Gone Viral: Bortezomib and oHSV Enhance Antitumor NK-Cell Activity.
-
Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma.
-
Immunotherapy Utilization Among Patients With Metastatic NSCLC: Impact of Comorbidities.
-
Immunotherapy With Programmed Cell Death 1 Inhibitors for 5 Patients With Conjunctival Melanoma.
-
Immunotherapy advances for glioblastoma.
-
Immunotherapy and Checkpoint Inhibitors in Recurrent and Metastatic Head and Neck Cancer.
-
Immunotherapy and monoclonal antibody therapies.
-
Immunotherapy and targeted-therapy combinations mark a new era of kidney cancer treatment.
-
Immunotherapy approaches for malignant glioma from 2007 to 2009.
-
Immunotherapy approaches in the treatment of malignant brain tumors.
-
Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma?
-
Immunotherapy following regional chemotherapy treatment of advanced extremity melanoma.
-
Immunotherapy for Brain Tumors.
-
Immunotherapy for Glioblastoma: Adoptive T-cell Strategies.
-
Immunotherapy for HIV.
-
Immunotherapy for Resected Pulmonary Metastases.
-
Immunotherapy for gynaecological malignancies.
-
Immunotherapy for osteosarcoma: Where do we go from here?
-
Immunotherapy for primary brain tumors: no longer a matter of privilege.
-
Immunotherapy for refractory pulmonary infection after adult cardiac surgery: immune dysregulation syndrome.
-
Immunotherapy in neonatal sepsis: advances in treatment and prophylaxis.
-
Immunotherapy in selected patients with Down syndrome disintegrative disorder.
-
Immunotherapy of B-cell malignancies with genetically engineered human CD8+ natural killer T cells.
-
Immunotherapy of brain tumors.
-
Immunotherapy of cancer using cytokine gene-modified tumor vaccines.
-
Immunotherapy of established murine squamous cell carcinoma using fused dendritic-tumor cell hybrids.
-
Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting.
-
Immunotherapy of malignant brain tumors.
-
Immunotherapy of type 1 diabetes: where are we and where should we be going?
-
Immunotherapy response assessment in neuro-oncology: a report of the RANO working group.
-
Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer.
-
Immunotherapy toxicities: An SGO clinical practice statement.
-
Immunotherapy using allogeneic squamous cell tumor-dendritic cell fusion hybrids.
-
Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease.
-
Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA.
-
Immunotherapy with tumor vaccines for the treatment of malignant gliomas.
-
Immunotherapy with vaccines combining MHC class II/CD80+ tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon gamma.
-
Immunotherapy, vascular pathology, and microhemorrhages in transgenic mice.
-
Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM.
-
Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors.
-
Implementation of a three-tiered approach to identify and characterize anti-drug antibodies raised against HIV-specific broadly neutralizing antibodies.
-
Improved killing of HIV-infected cells using three neutralizing and non-neutralizing antibodies.
-
Improved therapeutic efficacy of a monoclonal antibody radioiodinated using N-succinimidyl-3-(tri-n-butylstannyl)benzoate.
-
In situ stimulation of CD40 and Toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory cells.
-
In vitro synergism between hybrid immunotoxins and chemotherapeutic drugs: relevance to immunotherapy of prostate carcinoma.
-
In vivo evaluation of cell mediated immunity against human melanoma.
-
Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia.
-
Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy.
-
Induction of Wilms' tumor protein (WT1)-specific antitumor immunity using a truncated WT1-expressing adenovirus vaccine.
-
Induction of cellular immunity to Coccidioides immitis after sensitization with dinitrochlorobenzene.
-
Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells.
-
Inhibiting the TGF-beta signalling pathway as a means of cancer immunotherapy.
-
Inhibition of ALG3 stimulates cancer cell immunogenic ferroptosis to potentiate immunotherapy.
-
Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer.
-
Inhibition of established pancreatic cancers following specific active immunotherapy with interleukin-2 gene-transduced tumor cells.
-
Inhibition of the growth of human melanoma xenografts in nude mice by human tumor-specific cytotoxic T-cells.
-
Initial phase I/IIa trial results of an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in patients with solid tumors.
-
Injectable Therapies for Regional Melanoma.
-
Innovations and challenges in renal cancer: consensus statement from the first international conference.
-
Integrated safety data from 4 randomized, double-blind, controlled trials of autologous cellular immunotherapy with sipuleucel-T in patients with prostate cancer.
-
Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO).
-
Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202).
-
Interleukin-10: An Immune-Activating Cytokine in Cancer Immunotherapy.
-
Interleukin-15-Stimulated Natural Killer Cells Clear HIV-1-Infected Cells following Latency Reversal Ex Vivo.
-
Interleukin-2 immunotherapy and AIDS-related cytomegalovirus retinitis.
-
Interleukin-2 immunotherapy of murine cytomegalovirus retinitis during MAIDS correlates with increased intraocular CD8+ T-cell infiltration.
-
Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma.
-
Intratumoral delivery of brachytherapy and immunotherapy by a thermally triggered polypeptide depot.
-
Intravital optical imaging for immune cell tracking after photoimmunotherapy with plasmonic gold nanostars.
-
Investigative studies in the diagnosis and treatment of melanoma.
-
Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results.
-
Irradiation and immunotherapy: From concept to the clinic.
-
Is There a Role for Immunotherapy in Central Nervous System Cancers?
-
Keyhole limpet hemocyanin: structural and functional characterization of two different subunits and multimers.
-
Leptin Augments Antitumor Immunity in Obesity by Repolarizing Tumor-Associated Macrophages.
-
Lessons from two trials of mycophenolate mofetil in myasthenia gravis.
-
Lethal "thin" malignant melanoma. Identifying patients at risk.
-
Letter to the Editor: mRNA Vaccines in Urological Malignancies.
-
Ligand-independent toll-like receptor signals generated by ectopic overexpression of MyD88 generate local and systemic antitumor immunity.
-
Liver Tumor Microenvironment.
-
Long-Term Survival after Complete Surgical Resection and Adjuvant Immunotherapy for Distant Melanoma Metastases.
-
Low tumor mutational burden and immunotherapy in gliomas.
-
Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720.
-
Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV.
-
MCA106 fibrosarcoma cells transduced with granulocyte/macrophage colony-stimulating factor are not superior to the wild-type cells in suppressing the growth of hepatic metastases.
-
MRP3: a molecular target for human glioblastoma multiforme immunotherapy.
-
Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice.
-
Making progress in a rare disease: emerging therapeutics in soft tissue sarcomas.
-
Malignant melanoma and pregnancy.
-
Mammalian C-type oncornaviruses: relationships between viral structural and cell-surface antigens and their possible significance in immunological defense mechanisms.
-
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology.
-
Management of allergic rhinitis in the working-age population.
-
Management of glioblastoma: State of the art and future directions.
-
Management of recurrent melanoma of the extremity.
-
Mature T lymphocyte apoptosis--immune regulation in a dynamic and unpredictable antigenic environment.
-
Mechanism of immune response during immunotherapy.
-
Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors.
-
Melanoma immunotherapy using mature DCs expressing the constitutive proteasome.
-
Melanoma-Derived Wnt5a Promotes Local Dendritic-Cell Expression of IDO and Immunotolerance: Opportunities for Pharmacologic Enhancement of Immunotherapy.
-
Melanoma-specific cytotoxic T cells generated from peripheral blood lymphocytes. Implications of a renewable source of precursors for adoptive cellular immunotherapy.
-
Memory T cells.
-
Mesothelin, a novel immunotherapy target for triple negative breast cancer.
-
Messenger RNA (mRNA) nanoparticle tumour vaccination.
-
Metabolic Barriers to T Cell Function in Tumors.
-
Metabolic reprogramming of the immune response in the tumor microenvironment.
-
Metabolism in the tumor microenvironment: insights from single-cell analysis.
-
Metastatic clear cell renal cell carcinoma: Circulating biomarkers to guide antiangiogenic and immune therapies.
-
Migration of human dendritic cells after injection in patients with metastatic malignancies.
-
Minding the Bathwater: Fertility and Reproductive Toxicity in the Age of Immuno-Oncology.
-
Minimal Residual Disease in Chronic Lymphocytic Leukemia in the Era of Novel Agents: A Review.
-
Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-Enhanced Delivery of IL4R-Targeted Immunotoxin MDNA55 in Recurrent Glioblastoma.
-
Modulation of specific active immunization against murine melanoma using recombinant cytokines.
-
Molecular dissection of the miR-17-92 cluster's critical dual roles in promoting Th1 responses and preventing inducible Treg differentiation.
-
Molecular strategies for the treatment of malignant glioma--genes, viruses, and vaccines.
-
Monitoring cellular immune responses to cancer immunotherapy.
-
Monoclonal antibodies for brain tumour treatment.
-
Monoclonal antibodies to different epitopes on a prostate tumor-associated antigen. Implications for immunotherapy.
-
Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans.
-
Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance.
-
Monoclonal antibody therapy of human gliomas: current status and future approaches.
-
Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model.
-
Murine cytomegalovirus retinitis during retrovirus-induced immunodeficiency (MAIDS) in mice: interleukin-2 immunotherapy correlates with increased intraocular levels of perforin mRNA.
-
Murine monoclonal anti-T cell antibodies for treatment of steroid-resistant acute graft-versus-host disease.
-
Mutant p53 as an Antigen in Cancer Immunotherapy.
-
Myasthenia gravis: management of myasthenic crisis and perioperative care.
-
Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice.
-
Myelopoiesis during Solid Cancers and Strategies for Immunotherapy.
-
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020.
-
NCCN Guidelines Insights: Melanoma, Version 3.2016.
-
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020.
-
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021.
-
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016.
-
NCCN Guidelines® Insights: Squamous Cell Skin Cancer, Version 1.2022.
-
NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity.
-
Neuro-ophthalmic side effects of molecularly targeted cancer drugs.
-
Neuromuscular Disease in the Neurointensive Care Unit.
-
New Approaches to Glioblastoma.
-
New agents and regimens for diffuse large B cell lymphoma.
-
New and emerging treatments for advanced prostate cancer.
-
New drug development in metastatic prostate cancer.
-
New frontiers of immunotherapy for HIV.
-
New treatments for men with castration-resistant prostate cancer: can we move from small steps to giant leaps?
-
Non-Hodgkin's lymphomas.
-
Non-Operative Options for Loco-regional Melanoma.
-
Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.
-
Non-cholinergic strategies for treating and preventing Alzheimer's disease.
-
Non-specific and specific active immunotherapy in a B16 murine melanoma system.
-
Non-specific and specific immunotherapy in patients with melanoma.
-
Nondepleting anti-CD40-based therapy prolongs allograft survival in nonhuman primates.
-
Novel Therapies in Gynecologic Cancer.
-
Novel chemotherapies in development for management of castration-resistant prostate cancer.
-
Novel immunotherapeutic strategies in development for renal cell carcinoma.
-
Novel recombinant alphaviral and adenoviral vectors for cancer immunotherapy.
-
Novel therapeutic approaches to advanced prostate cancer.
-
Novel therapies for pancreatic adenocarcinoma.
-
Novel therapies for the treatment of advanced prostate cancer.
-
On the double: Early immunotherapy speeds recovery of ocular myasthenic weakness.
-
Once, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma.
-
Oncolytic immunotherapy through tumor-specific translation and cytotoxicity of poliovirus.
-
Oncolytic polio virotherapy of cancer.
-
Oncolytic viruses in melanoma.
-
One-unit versus two-unit cord-blood transplantation for hematologic cancers.
-
Ophthalmic Immune-Related Adverse Events of Immunotherapy: A Single-Site Case Series.
-
Opportunities for Radiosensitization in the Stereotactic Body Radiation Therapy (SBRT) Era.
-
Optimizing Advances in Nanoparticle Delivery for Cancer Immunotherapy.
-
Optimizing dendritic cell function by genetic modification.
-
Optimizing the efficiency and quality of sipuleucel-T delivery in an academic institution.
-
Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.
-
Outcomes of stage IV melanoma in the era of immunotherapy: a National Cancer Database (NCDB) analysis from 2014 to 2016.
-
Overview of melanoma vaccines and promising approaches.
-
PD-1 Inhibitors: Do they have a Future in the Treatment of Glioblastoma?
-
PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression.
-
PEG-ADA replacement therapy for adenosine deaminase deficiency: an update after 8.5 years.
-
Parkinson disease and the immune system - associations, mechanisms and therapeutics.
-
Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science.
-
Patient-derived micro-organospheres enable clinical precision oncology.
-
Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial.
-
Payer database and geospatial analysis to evaluate practice patterns in treating allergy in North Carolina.
-
Pediatric GAD-65 Autoimmune Encephalitis: Assessing Clinical Characteristics and Response to Therapy With a Novel Assessment Scale.
-
Perioperative Outcomes and Survival After Preoperative Immunotherapy for Non-Small Cell Lung Cancer.
-
Peripheral immune-based biomarkers in cancer immunotherapy: can we realize their predictive potential?
-
Perspectives on Treatment of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitor Therapy.
-
Pharmacokinetics and immunogenicity of broadly neutralizing HIV monoclonal antibodies in macaques.
-
Pharmacological Wnt ligand inhibition overcomes key tumor-mediated resistance pathways to anti-PD-1 immunotherapy.
-
Pharmacological effects of ex vivo mesenchymal stem cell immunotherapy in patients with acute kidney injury and underlying systemic inflammation.
-
Pharmacological inhibition of TGFβ as a strategy to augment the antitumor immune response.
-
Phase 1 Dose Escalation Study of MEDI-565, a Bispecific T-Cell Engager that Targets Human Carcinoembryonic Antigen, in Patients With Advanced Gastrointestinal Adenocarcinomas.
-
Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition [corrected].
-
Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies.
-
Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760).
-
Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas.
-
Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses.
-
Plasmonic gold nanostar-mediated photothermal immunotherapy for brain tumor ablation and immunologic memory.
-
Polyclonal immune responses to antigens associated with cancer signaling pathways and new strategies to enhance cancer vaccines.
-
Possibilities of immunotherapy and gene therapy for malignant melanoma.
-
Postexposure immunoprophylaxis of primary isolates by an antibody to HIV receptor complex.
-
Potential predictive biomarkers for individualizing treatment for men with castration-resistant prostate cancer.
-
Preclinical Evaluation of a Replication-Deficient Recombinant Adenovirus Serotype 5 Vaccine Expressing Guanylate Cyclase C and the PADRE T-helper Epitope.
-
Preclinical testing of a peptide-based, HER2/neu vaccine for prostate cancer.
-
Preconditioning Vaccine Sites for mRNA-Transfected Dendritic Cell Therapy and Antitumor Efficacy.
-
Preparation of peptide-loaded dendritic cells for cancer immunotherapy.
-
Prognostic Significance of Liver Metastasis in Durvalumab-Treated Lung Cancer Patients.
-
Program death-1 immune checkpoint and tumor microenvironment in malignant liver tumors.
-
Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients.
-
Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients.
-
Promising vaccines for treating glioblastoma.
-
Properties of mouse leukemia viruses. XIX. Effective antibody therapy of AKR leukemia occurs independently of virus neutralization and produces long-term changes in the virus status of the thymus.
-
Prospect of rindopepimut in the treatment of glioblastoma.
-
Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness.
-
Prospects for the immunological management of lethal tumors.
-
Prospects for treatment of human retrovirus-associated diseases.
-
Prospects for vaccine protection against HIV-1 infection and AIDS.
-
Prospects of immune checkpoint modulators in the treatment of glioblastoma.
-
Prostate cancer gene therapy.
-
Pushing Past the Blockade: Advancements in T Cell-Based Cancer Immunotherapies.
-
Putting Provenge in perspective.
-
Putting Provenge in perspective.
-
RNA transfected dendritic cells as cancer vaccines.
-
RNA-mediated immunotherapy regulating tumor immune microenvironment: next wave of cancer therapeutics.
-
RNA-transfected dendritic cells in cancer immunotherapy.
-
Racial Differences in Survival Among Advanced-stage Non-small-Cell Lung Cancer Patients Who Received Immunotherapy: An Analysis of the US National Cancer Database (NCDB).
-
Racial Disparity in Response to Prostate Cancer Systemic Therapies.
-
Radical Minimally Invasive Surgery After Immuno-chemotherapy in Initially-unresectable Stage IIIB Non-small cell Lung Cancer.
-
Rationale and emerging strategies for immune checkpoint blockade in soft tissue sarcoma.
-
Rationale for hypoxia assessment and amelioration for precision therapy and immunotherapy studies.
-
Rationing in urologic oncology: lessons from sipuleucel-T for advanced prostate cancer.
-
Recent advances in the search for a targeted immunomodulatory therapy for primary Sjögren's syndrome.
-
Recent developments in therapeutic cancer vaccines.
-
Recognition, Prevention, and Management of Arrhythmias and Autonomic Disorders in Cardio-Oncology: A Scientific Statement From the American Heart Association.
-
Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: "What's Past Is Prologue" (Shakespeare).
-
Recombinant Poliovirus for Cancer Immunotherapy.
-
Recurrent Glioblastoma Treated with Recombinant Poliovirus.
-
Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2.
-
Regulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice.
-
Replication-defective canarypox (ALVAC) vectors effectively activate anti-human immunodeficiency virus-1 cytotoxic T lymphocytes present in infected patients: implications for antigen-specific immunotherapy.
-
Reply to M.C. Chamberlain.
-
Reprograming immunity to food allergens.
-
Rescuing imperfect antigens for immuno-oncology.
-
Response to immunotherapy in a patient with Landau-Kleffner syndrome and GRIN2A mutation.
-
Results of a Phase I study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children with Stage 4 neuroblastoma.
-
Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme.
-
Role of Tumor-Mediated Dendritic Cell Tolerization in Immune Evasion.
-
Role of antibodies to murine leukemia virus p15E transmembrane protein in immunotherapy against AKR leukemia: a model for studies in human acquired immunodeficiency syndrome.
-
Role of dendritic cell metabolic reprogramming in tumor immune evasion.
-
SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery.
-
Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer.
-
Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals.
-
Sarcomatoid Renal Cell Carcinoma: An Immune Checkpoint-responsive Subset?
-
Secondary lymphoid tissue and costimulation-blockade resistant rejection: A nonhuman primate renal transplant study.
-
Sensitizing immune unresponsive colorectal cancers to immune checkpoint inhibitors through MAVS overexpression.
-
Sequential CT Findings in Patients With Non-small-cell Lung Cancer Receiving Nivolumab.
-
Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma.
-
Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors.
-
Serum elevation of B lymphocyte stimulator does not increase regulatory B cells in glioblastoma patients undergoing immunotherapy.
-
Serum soluble mesothelin-related protein (SMRP) and fibulin-3 levels correlate with baseline malignant pleural mesothelioma (MPM) tumor volumes but are not useful as biomarkers of response in an immunotherapy trial.
-
Setting a new standard for long-term survival in metastatic kidney cancer.
-
Significance of regional draining lymph nodes in the development of tumor immunity: implications for cancer immunotherapy.
-
Single cell analysis reveals distinct immune landscapes in transplant and primary sarcomas that determine response or resistance to immunotherapy.
-
Single-cell imaging of T cell immunotherapy responses in vivo.
-
Skindex-Mini Among Patients With Melanoma Who Have Cutaneous Immunotherapy-Related Adverse Effects.
-
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer.
-
Specific active immunotherapy for melanoma.
-
Specific cytotoxic antibody in the sera of patients with melanoma.
-
Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients.
-
Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer.
-
Stromal Fibroblasts Mediate Anti-PD-1 Resistance via MMP-9 and Dictate TGFβ Inhibitor Sequencing in Melanoma.
-
Successful tumour immunotherapy: possible role of antibodies to anti-inflammatory factors produced by neoplasms.
-
Supramolecular peptide vaccines: tuning adaptive immunity.
-
Surgical management of melanoma brain metastases in patients treated with immunotherapy.
-
Surrogate markers of effective anti-tumor immunity.
-
Surrogate markers of response to cancer immunotherapy.
-
Survival Outcomes of Sipuleucel-T Phase III Studies: Impact of Control-Arm Cross-Over to Salvage Immunotherapy.
-
Systematic review of combinations of targeted or immunotherapy in advanced solid tumors.
-
Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma.
-
Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells.
-
Systemic cytokine immunotherapy for experimental cytomegalovirus retinitis in mice with retrovirus-induced immunodeficiency.
-
Systemic strategies for prostate cancer.
-
Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer.
-
T cells specific for α-myosin drive immunotherapy-related myocarditis.
-
T helper subsets in allergic eye disease.
-
T-cell Dysfunction in Glioblastoma: Applying a New Framework.
-
T-cell-directed cancer vaccines: mechanisms of immune escape and immune tolerance.
-
TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts.
-
TRIGGERED: could refocused cell signaling be key to natural killer cell-based HIV immunotherapeutics?
-
Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial).
-
Targetable Immune Regulatory Molecule Expression in High-Grade Serous Ovarian Carcinomas in African American Women: A Study of PD-L1 and IDO in 112 Cases From the African American Cancer Epidemiology Study (AACES).
-
Targeted and untargeted CD137L fusion proteins for the immunotherapy of experimental solid tumors.
-
Targeting B-cells mitigates autoimmune diabetes in NOD mice: what is plan B?
-
Targeting Histone Deacetylase 6 Reprograms Interleukin-17-Producing Helper T Cell Pathogenicity and Facilitates Immunotherapies for Hepatocellular Carcinoma.
-
Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy.
-
Targeting N-cadherin enhances antitumor activity of cytotoxic therapies in melanoma treatment.
-
Targeting Neoantigens in Hepatocellular Carcinoma for Immunotherapy: A Futile Strategy?
-
Targeting PD-L1 Initiates Effective Antitumor Immunity in a Murine Model of Cushing Disease.
-
Targeting Tumor-Associated Antigens in Hepatocellular Carcinoma for Immunotherapy: Past Pitfalls and Future Strategies.
-
Targeting age-related macular degeneration with Alzheimer's disease based immunotherapies: anti-amyloid-beta antibody attenuates pathologies in an age-related macular degeneration mouse model.
-
Targeting cell surface F1F0 ATP synthase in cancer therapy.
-
Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma.
-
Technology evaluation: ipilimumab, Medarex/Bristol-Myers Squibb.
-
Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer.
-
Temozolomide treatment outcomes and immunotherapy efficacy in brain tumor.
-
Temperature matters! And why it should matter to tumor immunologists.
-
Tempering allorecognition to induce transplant tolerance with chemically modified apoptotic donor cells.
-
Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients.
-
The 12-CK Score: Global Measurement of Tertiary Lymphoid Structures.
-
The Cancer Epitope Database and Analysis Resource: A Blueprint for the Establishment of a New Bioinformatics Resource for Use by the Cancer Immunology Community.
-
The Complement Receptors C3aR and C5aR Are a New Class of Immune Checkpoint Receptor in Cancer Immunotherapy.
-
The Immunotherapy Landscape in Renal Cell Carcinoma.
-
The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients.
-
The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases.
-
The Role of Pediatric Rheumatologists in Autoimmune Brain Disease.
-
The Role of Targeted Therapy in the Management of High-Risk Resected Kidney Cancer: What Have We Learned and How Will It Inform Future Adjuvant Trials.
-
The Safety of available immunotherapy for the treatment of glioblastoma.
-
The Tumor Microenvironment Regulates CD19 and CD20 Immunotherapy for Lymphoma.
-
The challenges of checkpoint inhibition in the treatment of multiple myeloma.
-
The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target.
-
The current landscape of immunotherapy for pediatric brain tumors.
-
The current state of immunotherapy for gliomas: an eye toward the future.
-
The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients.
-
The effect of antibodies and immunotoxins reactive with HER-2/neu on growth of ovarian and breast cancer cell lines.
-
The effects of leukemosuppressive immunotherapy on thymic infectious cell centers in AKR mice.
-
The evolving role of gene-based treatment in surgery.
-
The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer.
-
The future of rheumatoid arthritis treatment.
-
The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors.
-
The immunologic constant of rejection.
-
The immunotherapeutic landscape in non-small cell lung cancer and its surgical horizons.
-
The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy.
-
The intersection between immunotherapy and laser interstitial thermal therapy: a multipronged future of neuro-oncology.
-
The management of bee hives.
-
The management of desmoid tumors.
-
The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice.
-
The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials.
-
The role of bone marrow and thymic elements in the initiation and spread of virus production in the AKR thymus.
-
The role of dendritic cell precursors in tumour vasculogenesis.
-
The role of immunotherapy in fusion-driven lung cancer.
-
The role of tregs in glioma-mediated immunosuppression: potential target for intervention.
-
The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC).
-
The treatment of colorectal carcinoma: standard chemotherapy and beyond.
-
The tumor microenvironment as a metabolic barrier to effector T cells and immunotherapy.
-
Therapeutic B cell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice.
-
Therapeutic aspects of chaperones/heat-shock proteins in neuro-oncology.
-
Therapeutic plasma exchange in the management of immune checkpoint inhibitor-associated immune-related adverse effects: A review.
-
Thoracic empyema associated with recurrent colon cancer: report of a case and review of the literature.
-
Tissue engineered cancer metastases as cancer vaccine to improve cancer immunotherapy.
-
Toll-like receptor agonists as third signals for dendritic cell-tumor fusion vaccines.
-
Top Ten Tips Palliative Care Clinicians Should Know About Managing Immune-Mediated Endocrine Toxicities in Cancer.
-
Top Ten Tips for Palliative Care Clinicians Caring for Cancer Patients Receiving Immunotherapies.
-
Toward effective immunotherapy for the treatment of malignant brain tumors.
-
Toward improved effectiveness of bladder cancer immunotherapy.
-
Transduction of human melanoma cells with the gamma interferon gene enhances cellular immunity.
-
Translational Research Working Group developmental pathway for immune response modifiers.
-
Translational impact of NIH-funded nonhuman primate research in transplantation.
-
Treatment options for newly diagnosed patients with chronic lymphocytic leukemia.
-
Treatment outcomes of surgery, antifungal therapy and immunotherapy in ocular and vascular human pythiosis: a retrospective study of 18 patients.
-
Tripartite antigen-agnostic combination immunotherapy cures established poorly immunogenic tumors.
-
Triple-hit B-cell Lymphoma With MYC, BCL2, and BCL6 Translocations/Rearrangements: Clinicopathologic Features of 11 Cases.
-
Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better?
-
Tumor antigens in astrocytic gliomas.
-
Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts.
-
Tumor lysate particle loaded dendritic cell vaccine: preclinical testing of a novel personalized cancer vaccine.
-
Tumor-dendritic cell fusion as a basis for cancer immunotherapy.
-
Tumor-intrinsic NLRP3-HSP70-TLR4 axis drives premetastatic niche development and hyperprogression during anti-PD-1 immunotherapy.
-
Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma.
-
Turning lemons into lemonade: learning from negative studies in cancer immunotherapy.
-
Type B CpG oligodeoxynucleotides induce Th1 responses to peanut antigens: modulation of sensitization and utility in a truncated immunotherapy regimen in mice.
-
Understanding the response to immunotherapy in humans.
-
Unique challenges for glioblastoma immunotherapy-discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank.
-
Updates in adjuvant systemic therapy for melanoma.
-
Use and Safety of Immunotherapeutic Management of N-Methyl-d-Aspartate Receptor Antibody Encephalitis: A Meta-analysis.
-
Use of intravenous gamma-globulin in antibody immunodeficiency: results of a multicenter controlled trial.
-
Utilization and impact of immunotherapy in stage IV melanoma using the National Cancer Database.
-
VEGF inhibitors in cancer therapy.
-
Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy.
-
Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy.
-
Videos of Sipuleucel-T Programmed T Cells Lysing Cells That Express Prostate Cancer Target Antigens.
-
What potential does plasmonics-amplified synergistic immuno photothermal nanotherapy have for treatment of cancer?
-
What's next for immunotherapy in locally advanced NSCLC?
-
Where We Stand With Immunotherapy in Colorectal Cancer: Deficient Mismatch Repair, Proficient Mismatch Repair, and Toxicity Management.
-
Whole blood cells loaded with messenger RNA as an anti-tumor vaccine.
-
X-linked inhibitor of apoptosis protein mediates tumor cell resistance to antibody-dependent cellular cytotoxicity.
-
[Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis].
-
[Antitumoral action of interferons and interleukins in combination with radiotherapy. Part II: radiobiological and immunologic strategies].
-
[Basis for a specific-active immunotherapy in malignant melanoma].
-
[In vivo evaluation of cellular immunity in melanoma patients against melanoma].
-
cDNA arrays and the enigma of melanoma immune responsiveness.
-
miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy.
-
miR-21 depletion in macrophages promotes tumoricidal polarization and enhances PD-1 immunotherapy.
-
miRNA expression in diffuse large B-cell lymphoma treated with chemoimmunotherapy.
-
Keywords of People
-
-
-
Berchuck, Andrew,
James M. Ingram Distinguished Professor of Gynecologic Oncology,
Obstetrics and Gynecology, Gynecologic Oncology
-
Bowes Rickman, Catherine,
George and Geneva Boguslavsky Distinguished Professor of Eye Research,
Cell Biology
-
Buckley, Rebecca Hatcher,
Professor Emeritus of Pediatrics,
Pediatrics, Allergy and Immunology
-
Choi, Taewoong,
Assistant Professor of Medicine,
Duke Cancer Institute
-
Cohen-Wolkowiez, Michael,
Professor of Pediatrics,
Pediatrics, Infectious Diseases
-
Donnelly, Christopher,
Assistant Professor in Anesthesiology,
Neurobiology
-
Farsiu, Sina,
Professor in the Department of Biomedical Engineering,
Electrical and Computer Engineering
-
Fecci, Peter Edward,
Professor of Neurosurgery,
Biomedical Engineering
-
Ferrari, Guido,
Professor in Surgery,
Molecular Genetics and Microbiology
-
Inman, Brant Allen,
Professor of Surgery,
Surgery, Urology
-
Khasraw, Mustafa,
Professor of Neurosurgery,
Medicine, Medical Oncology
-
Lee, Walter T,
Professor of Head and Neck Surgery & Communication Sciences,
Radiation Oncology
-
MacLeod, Amanda S,
Adjunct Associate Professor in the Department of Dermatology,
Immunology
-
McLendon, Roger Edwin,
Professor of Pathology,
Pathology
-
Mosca, Paul Joseph,
Associate Professor of Surgery,
Surgical Oncology
-
Mowery, Yvonne Marie,
Butler Harris Assistant Professor in Radiation Oncology,
Radiation Oncology
-
Pirozzi, Christopher,
Assistant Professor in Pathology,
Pathology
-
Sampson, John Howard,
Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine,
Biomedical Engineering
-
Shariff, Afreen Idris,
Assistant Professor of Medicine,
Medicine, Endocrinology, Metabolism, and Nutrition
-
Zhong, Pei,
Professor in the Department of Mechanical Engineering and Materials Science,
Thomas Lord Department of Mechanical Engineering and Materials Science
-
Zhong, Xiaoping,
Professor of Pediatrics,
Immunology